PNC Financial Services Group’s Tourmaline Bio TRML Stock Holding History

PNC Financial Services Group’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20	Closed	-$957	–	5307
2025 Q3	$957	Hold	20	–	–	﹤0.01%	4684
2025 Q2	$320	Buy	+20	New	+$324	﹤0.01%	4747
2023 Q4	–	Sell	-193	Closed	-$5.41K	–	4765
2023 Q3	$5.41K	Hold	193	–	–	﹤0.01%	3974
2023 Q2	$5.85K	Sell	193 -9	-4%	-$230	﹤0.01%	4070
2023 Q1	$3.79K	Buy	+202	New	+$3.33K	﹤0.01%	4131

PNC Financial Services Group's TRML Position: Q4 2025 in Review

PNC Financial Services Group sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 20 shares — an estimated $957 sold.

PNC Financial Services Group first reported a position in TRML in Q1 2023 and held it in 5 quarters. The position peaked at $5.85K in Q2 2023. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

PNC Financial Services Group reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
PNC Financial Services Group sold 20 Tourmaline Bio shares in Q4 2025, an estimated $957.
PNC Financial Services Group first reported a position in Tourmaline Bio in Q1 2023 and held it in 5 quarters.
PNC Financial Services Group's Tourmaline Bio position peaked at $5.85K in Q2 2023.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on PNC Financial Services Group's 13F filing for Q4 2025, filed 6 Feb 2026.